- Home
- SBGI vs VIR Comparison
SBGI vs VIR Comparison
Compare SBGI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- VIR
- Stock Information
- Founded
- SBGI 1986
- VIR 2016
- Country
- SBGI United States
- VIR United States
- Employees
- SBGI N/A
- VIR N/A
- Industry
- SBGI Broadcasting
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- VIR Health Care
- Exchange
- SBGI Nasdaq
- VIR Nasdaq
- Market Cap
- SBGI 886.6M
- VIR 773.5M
- IPO Year
- SBGI 1995
- VIR 2019
- Fundamental
- Price
- SBGI $15.92
- VIR $6.35
- Analyst Decision
- SBGI Buy
- VIR Strong Buy
- Analyst Count
- SBGI 5
- VIR 11
- Target Price
- SBGI $21.00
- VIR $25.73
- AVG Volume (30 Days)
- SBGI 595.5K
- VIR 1.5M
- Earning Date
- SBGI 11-05-2025
- VIR 11-05-2025
- Dividend Yield
- SBGI 6.34%
- VIR N/A
- EPS Growth
- SBGI N/A
- VIR N/A
- EPS
- SBGI N/A
- VIR N/A
- Revenue
- SBGI $3,337,000,000.00
- VIR $16,860,000.00
- Revenue This Year
- SBGI N/A
- VIR N/A
- Revenue Next Year
- SBGI $9.50
- VIR $15.25
- P/E Ratio
- SBGI N/A
- VIR N/A
- Revenue Growth
- SBGI N/A
- VIR N/A
- 52 Week Low
- SBGI $11.89
- VIR $4.16
- 52 Week High
- SBGI $18.46
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- SBGI 55.53
- VIR 64.60
- Support Level
- SBGI $14.52
- VIR $5.32
- Resistance Level
- SBGI $17.88
- VIR $5.86
- Average True Range (ATR)
- SBGI 0.88
- VIR 0.36
- MACD
- SBGI -0.07
- VIR 0.08
- Stochastic Oscillator
- SBGI 40.96
- VIR 89.97
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.